Back to News
Market Impact: 0.35
Biomea Shares Rise Ahead Of Phase I Data Readout For Obesity Drug BMF-650
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Biomea Fusion is scheduled to release Phase I GLP-131 data for its investigational obesity candidate BMF-650 on October 13, 2026. Shares rose 6.44% to $1.44 in premarket trading ahead of the readout; no clinical results were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
BMEA0.20
More News
- Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- Wells Fargo CFO on Earnings, Deals, Consumer Strength
- Bank of America hit with more than $1.2 billion in penalties over money-laundering violations
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it